Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Altimmune Inc
ALTCurrent price
7.06 USD
+0.2 USD (+2.92%)
Last closed
6.94 USD
Company
altimmune.com
ISIN
US02155H2004
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
640 121 408 USD
Yield for 12 month
-24.49 %
1Y
3Y
5Y
10Y
15Y
ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. Address: 910 Clopper Road, Gaithersburg, MD, United States, 20878
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
22.86 USDP/E ratio
–Dividend Yield
–Current Year
+426 000 USD
Last Year
-68 000 USD
Current Quarter
+5 000 USD
Last Quarter
+5 000 USD
Current Year
-51 000 USD
Last Year
-136 000 USD
Current Quarter
+5 000 USD
Last Quarter
-56 000 USD
Key Figures ALT
1 year
3 years
5 years
10 years
EBITDA
-99 191 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-39.56 %
PEG Ratio
–
Return On Equity TTM
-72.96 %
Wall Street Target Price
22.86 USD
Revenue TTM
52 000 USD
Book Value
1.88 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-98.60 %
Dividend Yield
–
Gross Profit TTM
-70 520 000 USD
Earnings per share
-1.57 USD
Diluted Eps TTM
-1.57 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ALT
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History ALT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
20.01.2017
Forward Annual Dividend Yield
–
Last Split Factor
1:30
Payout Ratio
–
Last Split Date
14.09.2018
Dividend Date
14.09.2018
Stock Valuation ALT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
9 663.74
Price Sales TTM
12 310.03
Enterprise Value EBITDA
-4.20
Price Book MRQ
4.80
Financials ALT
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ALT
For 52 weeks
5.28 USD
14.84 USD
50 Day MA
7.66 USD
Shares Short Prior Month
22 836 787
200 Day MA
7.50 USD
Short Ratio
5.81
Shares Short
23 434 782
Short Percent
33.04 %
BeatStart